Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
Laszlo Urban
No relevant relationships to disclose
Allen Poma
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Michelle Motta Dardeno
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro